These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32777553)

  • 1. Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I; van Leerdam ME
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1418-1425. PubMed ID: 32777553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
    Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program.
    van der Vlugt M; Grobbee EJ; Bossuyt PM; Bos ACRK; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1237-1243.e2. PubMed ID: 29427732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).
    Breekveldt ECH; Toes-Zoutendijk E; de Jonge L; Spaander MCW; Dekker E; van Kemenade FJ; van Vuuren AJ; Ramakers CRB; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    BMC Gastroenterol; 2023 Feb; 23(1):45. PubMed ID: 36814185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interval post-colonoscopy colorectal cancer following a negative colonoscopy in a fecal immunochemical test-based screening program.
    van de Schootbrugge-Vandermeer HJ; Kooyker AI; Wisse PHA; Nagtegaal ID; Geuzinge HA; Toes-Zoutendijk E; de Jonge L; Breekveldt ECH; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Lansdorp-Vogelaar I; Spaander MCW; van Leerdam ME
    Endoscopy; 2023 Dec; 55(12):1061-1069. PubMed ID: 37793423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Rate of Cancer Detection by Colonoscopy in Asymptomatic, Average-Risk Subjects with Negative Results From Fecal Immunochemical Tests.
    Longstreth GF; Anderson DS; Zisook DS; Shi JM; Lin JC
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2929-2936.e1. PubMed ID: 32007541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Quarter of Participants With Advanced Neoplasia Have Discordant Results From 2-Sample Fecal Immunochemical Tests for Colorectal Cancer Screening.
    Wieten E; de Klerk CM; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1805-1811.e1. PubMed ID: 31563557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
    de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
    Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
    Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short Term Outcomes of Using Fecal Immunochemical Test for a Pilot Colorectal Cancer Screening Program. A Single Center Study on 3024 Consecutive Patients.
    Constantin A; Cazacu I; Ciocârlan M; Constantinescu C; Baltog G; Balahura C; Doraş I; Filip S; Filip G; Panazan I; Piţigoi D; Pirvu V; Turcu F; Copăescu C; Săftoiu A
    Chirurgia (Bucur); 2020; 115(4):448-457. PubMed ID: 32876018
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk factors for colorectal cancer in a fecal immunochemical test-positive group: The National Health Insurance Service-National Health Screening Cohort.
    Park JH; Cho KH; Choi J; Chun S; Lee JK; Cho H; Kim B
    J Gastroenterol Hepatol; 2024 Jan; 39(1):74-80. PubMed ID: 37855299
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.